Antibody Dependent Enhancement

The current mRNA and adenovirus vaccines are creating a worse outcome.

This study focuses on vaccines that were developed for 1st generation of Wuhan virus also named Alpha strain. With the emergence of Delta, how effective is the vaccine? The possibility of ADE should be further investigated as it may represent a potential risk for mass vaccination during the current Delta variant pandemic.

Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? – Journal of Infection

If there is one principle in immunology that doesn’t work, it’s clearly ´the more, the better’. More antibodies or higher titers in large parts of the population (‘mass boosting’) will only dramatically increase immune pressure on delta’s infectiousness (i.e., on spike protein). The virus will respond with a selection of a mutation that simply prevents antibodies from binding to the receptor-binding domain (RBD) of the virus ( just like the less infectious lambda variant did as a result of enhanced immune pressure). This is a phenomena that typically unfolds at the population level and of course not in a clinical study on a limited number of subjects. So, what will happen is that, as a result a further increase in population-level immune pressure, delta will in no time select and breed an additional mutation that now enables to combine a high level of infectiousness with resistance to antibodies that bind to its RBD. That’s the super variant molecular epidemiologists have been warning against.

Geert Vanden Bossche on Linkedin, August 21 2021

And now there is proof of Antibody Resistant strain of SARS-Cov-2 in San Francisco:

Fully vaccinated were more likely than unvaccinated persons to be infected by variants carrying mutations associated with decreased antibody neutralization

Vaccine breakthrough infections were found to be associated with low or undetectable neutralizing antibody levels attributable to immunocompromised state or infection by an antibody-resistant lineage. These findings suggest that vaccine breakthrough cases are preferentially caused by circulating antibody-resistant SARS-CoV-2 variants, and that symptomatic breakthrough infections may potentially transmit COVID-19 as efficiently as unvaccinated infections, regardless of the infecting lineage.

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California